|
|
| | Danicamtiv Basic information |
| Product Name: | Danicamtiv | | Synonyms: | Danicamtiv;MYK-491;Danicamtiv (MYK-491);SAR 440181;Inhibitor,allosteric,cardiac,function,inhibit,Myosin,Danicamtiv,acto-myosin,inotropic,systolic,MYK 491,MYK491;1-Piperidinecarboxamide, 4-[(1R)-1-[[3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl]sulfonyl]-1-fluoroethyl]-N-3-isoxazolyl-;anicamtiv;Danicamtiv, 10 mM in DMSO | | CAS: | 1970972-74-7 | | MF: | C16H20F3N5O4S | | MW: | 435.42 | | EINECS: | | | Product Categories: | | | Mol File: | 1970972-74-7.mol |  |
| | Danicamtiv Chemical Properties |
| Boiling point | 699.1±55.0 °C(Predicted) | | density | 1.57±0.1 g/cm3(Predicted) | | solubility | DMSO:50.0(Max Conc. mg/mL);114.83(Max Conc. mM) | | form | A solid | | pka | 13.32±0.40(Predicted) | | color | Off-white to light yellow |
| | Danicamtiv Usage And Synthesis |
| Uses | Danicamtiv (MYK-491), an inotropic agent, is a selective allosteric activator of cardiac myosin. Danicamtiv increases cardiac systolic function and preserves mechanical efficiency[1]. | | in vivo | Danicamtiv selectively enhances cardiac actomyosin activity, the molecular force‐generating unit of the sarcomere, prolonging contraction while preserving actin–myosin detachment, allowing relaxation, and without impacting Ca2+ homeostasis[2]. | | References | [1] Sarah Fernandes, et al. Abstract 15707: MYK-491, a Novel Small-Molecule Cardiac Myosin Activator Increases Cardiac Systolic Function and Preserves Mechanical Efficiency: Pre-Clinical in vivo and in vitro Evidence. Circulation. 2019;140:A15707
[2] Voors AA, et al. Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. Eur J Heart Fail. 2020;22(9):1649-1658. DOI:10.1002/ejhf.1933 |
| | Danicamtiv Preparation Products And Raw materials |
|